Fesoterodine experience in women with overactive bladder syndrome

Introduction. Overactive bladder (OAB) is a symptom complex accompanied by urgency, nicturia with or without urinary incontinence and frequent urination, in the absence of a proven infection or other obvious pathology of the lower urinary tract. The first line of OAB therapy, currently believing, is pharmacotherapy with muscarinic receptor antagonists. One of them is fesoterodine.The aim of our study was to examine the efficacy of fesoterodine in the treatment of women with overactive bladder syndrome Materials and methods.The study included 60 women with symptoms of OAB. Age from 20 to 45 years. All women were given the drug fesoterodine (Toviaz®, Pfizer) at a dosage of 4 mg 1 time per day, which they took for 8 weeks. After 8 weeks (day 60), the efficacy and safety of treatment was assessed. According to the results of an 8-week course of therapy, the patients were divided into two groups. Group 1 included women in whom the therapy was effective (reduction in the number of infections, absence of nocturia and urgent urges)...